?
This announcement replaces the original announcement released on 3 January 2014 at 9.43am (RNS No: 8550W).
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc (the Company).
On 31 December 2013, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and ADSs in the Company through the annual reinvestment of dividends paid throughout 2013; calculated using an average price of £16.073 per Ordinary Share and $53.170 per ADS:
Non-Executive Director | Ordinary Shares | No. of ADSs |
Sir Christopher Gent | 4,466.364 | |
Prof Sir Roy Anderson | 685.862 | |
Dr Stephanie Burns | 538.531 | |
Stacey Cartwright | 125.504 | |
Lynn Elsenhans | 78.145 | |
Judy Lewent | 80.720 | |
Sir Deryck Maughan | 1,379.853 | |
Dr Daniel Podolsky | 968.774 | |
Tom de Swaan | 998.268 | |
Jing Ulrich | 24.625 | |
Hans Wijers | 3.630 | |
Sir Robert Wilson | 1,032.435 |
The Company and the Non-Executive Directors were informed of these allocations on 2 January 2014.
This notification relates to transactions notified in accordance withDisclosure and Transparency Rule 3.1.4R(1)(a).
Sonja Arseni?
Corporate Secretariat
15 January 2014
This information is provided by RNS
distributed by
|